BrIDGs is not a grant program. Instead of receiving grant funds, selected investigators partner with NIH intramural scientists to complete preclinical therapy development studies at no cost to the investigator. Collaborators leverage BrIDGs expertise and resources to generate data for a Investigational New Drug applications to a regulatory authority such as the Food and Drug Administration.
BrIDGs enables collaborations on potential therapies for any disease or disorder. Eligible collaborating organizations include academic institutions, not-for-profit organizations and small businesses eligible for the Small Business Innovation Research program. Foreign academic and nonprofit institutions as well as NIH intramural researchers may collaborate with BrIDGs.
Learn more about working with BrIDGs:
- How to Request a Collaboration: Overview of the request process and detailed instructions for investigators
- Considerations for Collaborators: Minimum data requirements and scope limitations for collaborations
- Intellectual Property: How BrIDGs handles background versus new intellectual property created during the project
- Project Implementation and Conduct: Project management, oversight and governance
- Resubmission of Prior Proposals: How to reapply and what must be achieved in the interim